$Tesla (TSLA.US)$ Today's review mainly continued the overnight call from yesterday. I saw the rally at the end of yesterday and without hesitation chased after it, betting that today would open higher. The result was lucky, closing right after the market opened, all easy and relaxed.
Originally, after clearing the call, I planned to continue observing but unexpectedly it immediately dropped. Decisively continued to chase the call, the logic inside is very simple, a sudden drop means there will be a certain level of rally.
Furthermore, when it rallied to 480, I noticed signs of the dissipation of the bull momentum, hence immediately put as shown in the chart. Once again gained 30% profit from the puts, the fluctuations today truly made me comfortable.
Finally, upon reviewing, the earnings from the beginning of this week have not been as much as before. I still feel that the prices are relatively high with a high probability of falling back at any time, so I am very conservative in my trades. Fortunately, I have been consistently earning. Truly grateful.
I still want to remind everyone to be cautious, better to earn less and lose less, and to control the position well. Otherwise, it will only lead to losses and defeat. $NVIDIA (NVDA.US)$ $Invesco QQQ Trust (QQQ.US)$ I'm about to go check on my other child, nvda.

Its Friday with shorter trading time. Sleepy already. Some will run and some will get delayed market reaction.
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...

$Cognition Therapeutics (CGTX.US)$ Will the train come down to pick up people? Waiting at 0.6.

$Cognition Therapeutics (CGTX.US)$ Hehehe🥂💸

$Cognition Therapeutics (CGTX.US)$
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
Cognition Therapeutics (NASDAQ: CGTX) presented baseline characteristics of participants in their Phase 2 'SHIMMER' study for dementia with Lewy bodies (DLB) at the CTAD conference. The study includes 130 participants with these key characteristics: mean age of 72.8 years, 81.5% male, 91.5% white, with mild-to-moderate cognitive impairment....

$Cognition Therapeutics (CGTX.US)$
Cognition Therapeutics (NASDAQ: CGTX)reported new biomarker analysis from their Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. The analysis revealed that patients with lower baseline plasma p-tau217 levels treated with CT1812 showed a 95% reduction in cognitive decline compared to placebo, representing a 2.7-point improvement on ADAS-Cog11 over six months. The study demonstrated normalization of key Alzheimer's disease indicators, including r...